Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, I think the team has done a really nice job of positioning KEYTRUDA so that we can continue to benefit and patients benefit over time |
| When I look -- so for HIV, so when you look at the work that the team has done to get islatravir back on track with doravirine, we're very excited for this opportunity given the fact that there's still tremendous need out there |
| In the earlier stage setting, we've done a really nice job, it's about 20% |
| We're excited, right? And so I think this is a great opportunity because number one, it's focused on the right thing |
| So, I would just say, I think we've been making steady progress in an important vaccine that covers a lot of different diseases |
| And over time, we continue to -- we have a great life cycle management program |
| We feel very confident in that process |
| And I think we've made steady progress since putting that outlook out there, and we continue to see as an opportunity we continue to view that by 2030, we'd be greater than $11 billion |
| So, we feel good about VAXNEUVANCE |
| So, everyone at Merck is extremely excited about sotatercept |
| But we feel really good about the progress to date |
| and we're able to get access to all the hospitals in China, which helped to drive growth |
| business? Joe Romanelli I would follow the fact that I think our competitive advantage is our lapse I think under Dean's leadership, I think they've done a fantastic job |
| And for VAXNEUVANCE, we felt really good because if you look at the disease severity, particularly in the first year of life and serotype 3, there's strong coverage there |
| We were happy that we got a positive opinion from the CHMP, look forward to that |
| And If you look at the study, our Phase III study, we cover 83% of the disease, right? So we feel very good about the health economics |
| So, if we can do that with a subcu formulation, I think that's kind of -- it will improve care will improve the ability for the hospitals to manage for patients who are going in for IV |
| And then Caroline, making sure we have the right valuation on those deals, have done a fantastic job, whether it's ADCs, neoantigen therapy or other co-formulations that we can have to try to deepen the impact of KEYTRUDA |
| So having a solution that covers 80% efficacy of and covers the 4 serotypes is outstanding |
| This is a great opportunity because the impact sotatercept can have on PAH patients |
| So, let's move to another very successful Merck product, that being KEYTRUDA |
| And this is a head-to-head with Vitrakvi, so this is an opportunity for us to really demonstrate differentiation |
| Triple-negative breast, there's very robust screening programs in the world |
| So women are identified their screen, they're diagnosed, and we can get them on treatment early, which is fantastic |
| It's done a great job to make sure that we can reach those other markets that we haven't yet reached, not only low middle income, but there are markets where we yet to launch GARDASIL 9 |
| We've made steady progress there |
| That's a great partnership, and Dean is very -- works very closely with that organization to make sure that we have the right studies in place that we can benefit the most patients to that |
| And through that time, we've been able to introduce new products |
| So that's another opportunity |
| And if you look at GARDASIL, we've had a phenomenal time over the past 18 years, really launching in new markets |
| Statement |
|---|
| I lived in Southeast Asia when we had an issue in Singapore, and it caused disruption to travel, schools, workforce, et cetera |
| And what we found is when we have products that have unambiguous promotable advantages |
| Our only experience with dengue with a competitor wasn't so good |
| I will say that the screening opportunity in O-U.S., particularly Europe is even lower than the U.S., and we talk about 6% screening in the U.S |
| And interestingly, one of your competitors, Roche, has basically told analysts not to expect much growth out of Tecentriq because they claim the market is saturated |
| So, we talk about all the geopolitical issues and certainly, we're mindful of those |
| Now I guess, saturation could occur either because the markets are truly saturated or KEYTRUDA is giving no opportunity to grow |
Please consider a small donation if you think this website provides you with relevant information